IPlex Approval History
FDA Approved: Yes (First approved December 12, 2005)
Brand name: iPlex
Generic name: mecasermin rinfabate [rDNA origin]
Dosage form: Injection
Previous Name: SomatoKine
Company: Insmed Incorporated
Treatment for: Primary IGF-1 Deficiency
iPlex (mecasermin rinfabate) is the human recombinant of the naturally occurring protein complex of insulin-like growth factor-I (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). iPlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Development History and FDA Approval Process for iPlex
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.